Sign In
Buy RDHL
$1.00
-0.0100 (-0.99%)
At Close: Jun 03, 2026
RedHill Announces Two New U.S. Patents
07:05am, Monday, 23'rd Aug 2021
RedHill Biopharma Announces Two New U.S. Patents Covering Opaganib for Ebola Virus and RHB-104 for Crohn's U.S. patents for opaganib combination for the treatment of Ebola virus disease provides paten
RedHill Biopharma Announces Two New U.S. Patents Covering Opaganib for Ebola Virus and RHB-104 for Crohn's
07:00am, Monday, 23'rd Aug 2021
TEL AVIV, Israel and RALEIGH, N.C., Aug. 23, 2021 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill Biopharma to Host Second Quarter 2021 Financial Results and Operational Highlights Webcast on August 26, 2021
07:00am, Thursday, 19'th Aug 2021
TEL AVIV, Israel and RALEIGH, NC, Aug. 19, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will
RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with Apotex
09:19am, Thursday, 22'nd Jul 2021
TEL AVIV, Israel and RALEIGH, NC, July 22, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that RedHill
RedHill Extends Talicia Commercial Coverage
08:00am, Tuesday, 20'th Jul 2021
RedHill Biopharma Significantly Extends Unrestricted Commercial Coverage for Talicia ® with OptumRx Addition of Talicia® by OptumRx significantly extends Commercial patient access to Talicia® throu
RedHill Biopharma Significantly Extends Unrestricted Commercial Coverage for Talicia® with OptumRx
07:00am, Tuesday, 20'th Jul 2021
TEL-AVIV, Israel and RALEIGH, N.C., July 20, 2021 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill Biopharma completes treatment and follow-up in the 475-patient global Phase 2/3 COVID-19 study with opaganib
10:16am, Monday, 19'th Jul 2021
RedHill Biopharma (NASDAQ: RDHL) has announced that all treatment and follow-up has now been completed in the 475-patient global Phase 2/3 study with opaganib (ABC294640) in patients hospitalized with
RedHill Biopharma Ltd Announces RedHill Biopharma Announces Last Patient Out
10:15am, Monday, 19'th Jul 2021
RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib Patient follow-up completed for the 475-patient global Phase 2/3 study of oral opaganib for severe COVID-19
RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib
07:00am, Monday, 19'th Jul 2021
TEL AVIV, Israel and RALEIGH, NC, July 19, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty pharma company that is a leader in the development of no
TEL-AVIV, Israel and RALEIGH, N.C., July 13, 2021 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill Biopharma Ltd. (NASDAQ:RDHL) has announced preliminary results from a new preclinical study showing potent inhibition of coronavirus (COVID-19) variants of concern by opaganib.
RedHill Biopharma's Opaganib Inhibits COVID-19 Variants in Preclinical Study
07:00am, Monday, 28'th Jun 2021
TEL AVIV, Israel and RALEIGH, N.C., June 28, 2021 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill Biopharma presents positive Phase 2 data for oral opaganib in hospitalized patients with COVID-19 at World Microbe Forum
06:07am, Tuesday, 22'nd Jun 2021
RedHill Biopharma Ltd. (NASDAQ:RDHL) has said it is setting the pace in the global quest for an oral COVID-19 treatment, with two oral COVID-19 drug candidates amongst the most advanced in development
RedHill Biopharma Announces Presentation of Positive Oral Opaganib Phase 2 Data in COVID-19
07:00am, Monday, 21'st Jun 2021
TEL AVIV, Israel and RALEIGH, NC, June 21, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced presentation
3 Top Biotech Picks for June
06:00am, Saturday, 19'th Jun 2021
Coronavirus players may deliver strong returns well into the future.
